BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models

Drug-tolerant “persister” tumor cells underlie emergence of drug-resistant clones and contribute to relapse and disease progression. Here we report that resistance to the BCL-2 targeting drug ABT-199 in models of mantle cell lymphoma and double-hit lymphoma evolves from outgrowth of persister clones...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Cell
Auteurs principaux: Zhao, Xiaohong, Ren, Yuan, Lawlor, Matthew, Shah, Bijal D., Park, Paul M.C., Lwin, Tint, Wang, Xuefeng, Liu, Kenian, Wang, Michelle, Gao, Jing, Li, Tao, Xu, Mousheng, Silva, Ariosto S., Lee, Kaplan, Zhang, Tinghu, Koomen, John M., Jiang, Huijuan, Sudalagunta, Praneeth R., Meads, Mark B., Cheng, Fengdong, Bi, Chengfeng, Fu, Kai, Fan, Huitao, Dalton, William S., Moscinski, Lynn C., Shain, Kenneth H., Sotomayor, Eduardo M., Wang, Gang Greg, Gray, Nathanael S., Cleveland, John L., Qi, Jun, Tao, Jianguo
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6945775/
https://ncbi.nlm.nih.gov/pubmed/31085176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2019.04.005
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires